Drugs / BI 1021958
last change Dec 2014 re-read 2 minutes ago

BI 1021958

Developed for
asthma
Investigated by
Boehringer Ingelheim

Trials 4 · a red edge is where a trial was stopped

2012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1 NCT02202512 Sep → Dec 2014 Boehringer Ingelheim Completed No outcome recorded
Phase 1 NCT01629849 Jul → Dec 2012 asthma Boehringer Ingelheim Completed No outcome recorded
Phase 1 NCT01638598 Jul → Aug 2012 Boehringer Ingelheim Completed No outcome recorded
Phase 1 NCT01541488 Feb → May 2012 Boehringer Ingelheim Completed No outcome recorded

Evidence & citations 2 cited values

Every value below carries the sentence it was read from. 4 sources stand behind the page.

FieldValueCited text
Known as BI 1021958 “Single Rising Oral Doses of BI 1021958 in Healthy Chinese and Japanese Male Volunteers” NCT01638598
3

NCT01629849

NCT02202512

NCT01541488

Route Oral “Single Rising Oral Doses” NCT01541488